Fosgonimeton is an investigational new drug that is being evaluated to treat neurodegenerative diseases such as Alzheimer's and Parkinson's disease.[1] It is a pro-drug of the active metabolite dihexa. Dihexa in turn binds to the hepatocyte growth factor (HGF) and potentiates its activity at its receptor, c-Met.[2]

References

  1. ^ "Fosgonimeton - Athira Pharma". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Reda SM, Setti SE, Berthiaume AA, Wu W, Taylor RW, Johnston JL, et al. (April 2024). "Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease". Neurotherapeutics. 21 (4): e00350. doi:10.1016/j.neurot.2024.e00350. PMC 11067346. PMID 38599894.


Allikas: https://en.wikipedia.org/wiki/Fosgonimeton
No tags for this post.